| Autor: |
Bengtsson, Bengt-Ola S, van Houten, John P |
| Předmět: |
|
| Zdroj: |
Journal of Patient Safety & Risk Management; Apr2024, Vol. 29 Issue 2, p115-118, 4p |
| Abstrakt: |
Background: Rhesus (Rh) D Immunoglobulin (RhIG), (Rhogam®) is indicated for all pregnant Rh-negative women at 28 weeks of gestation followed by a second dose within 72 h after birth if the newborn is Rh-positive and it reduces the risk for Rh alloimmunization of the mother from 13%–16% to 0.1%–0.2%. Methods: Retrospective review of causes and outcomes of two cases of Rh-induced hemolytic disease of the newborn (Rh-HDN) at our institution. Results: The determination of passive anti-D from RhIG versus active anti-D from maternal sensitization and subsequent management, relies entirely on a reliable history of prior and timely RhIG administration in the mother. Conclusion: These two cases illustrate the importance of communication (and the detriment of the lack thereof) between blood bank and maternal—and neonatal care providers in the prevention—and management of Rh-HDN. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
